ClinicalTrials.gg
RecruitingNCT07041281IMPACT-HTUpdated Apr 3, 2026

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

A Phase 2 interventional study of spironolactone 25 mg orally once daily and Placebo tablet to match spironolactone in Preeclampsia and Gestational Hypertension, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.

Planned enrollment
35th of 161
204 · median 89
Started
2025
with 12 others
Phase 2
18 of 230
7 open now
Primary completion
2027-12
later than 48 of 77 live
Registered
202nd of 230
by date
Lead sponsor
6 of 230
Massachusetts General Hospital

Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 35th largest by planned enrollment of the 161 interventional ones that give a count, is one of 13 that started in 2025, is one of 18 in phase 2, reaches primary completion later than 48 of the 77 other live ones, and was the 202nd registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Pre-Eclampsia with a site in United States, or all of them as a file.
02

Study summary

The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.

Read the detailed description

The hypertensive disorders of pregnancy (HDP, e.g., gestational hypertension and preeclampsia) are a leading cause of maternal and infant morbidity and mortality and are associated with increased long-term risk of maternal atherosclerotic cardiovascular disease (CVD) and heart failure. The American College of Cardiology and American Heart Association now recognize the HDP as a sex-specific CVD risk factor to guide prescription of preventive statin therapy. Beyond this focused recommendation, however, targeted strategies for CVD risk reduction in women with HDP are not yet established. Maternal overweight/obesity is a risk factor for accelerated progression from HDP to chronic hypertension, a key mediator of heightened long-term CVD risk in women with a history of HDP, and for adverse cardiac remodeling in pregnancy. Recent preclinical evidence suggests that the HDP induce heightened vascular smooth muscle cell mineralocorticoid receptor (MR) sensitivity that persists postpartum, promoting chronic hypertension and CVD. In addition, the recent POP-HT trial suggested that blood pressure control in the very early postpartum period has long-lasting effects on the risk of chronic hypertension and cardiac remodeling in women after HDP. Integrating these lines of evidence, the investigators hypothesize that short-term pharmacologic blockade of the MR in the early postpartum period after HDP will yield long-term maternal cardiovascular benefits in women with overweight/obesity. To test this hypothesis, the investigators will compare a strategy of adding low-dose spironolactone, a breastfeeding-compatible MR antagonist, or placebo to usual care for 3 months following delivery with HDP. This multi-site trial will randomize 204 women with HDP and pre-pregnancy overweight/obesity delivering at Massachusetts General Hospital, Brigham and Women's Hospital, and the University of Pittsburgh-Magee Womens Hospital. The investigators will test the effect of short-term adjunctive postpartum spironolactone on 24-hour ambulatory blood pressure (Aim 1) and postpartum cardiac remodeling by echocardiography (Aim 2) at 9 months postpartum (i.e., 6 months after completion of study treatment).

03

Conditions studied

  • Preeclampsia
  • Gestational Hypertension

Keywords

  • preeclampsia
  • gestational hypertension
  • spironolactone
  • blood pressure
  • hypertension
  • pregnancy
  • echocardiography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged ≥18 years
  • HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension
  • ≥25 kg/m2 prior to pregnancy or in the first trimester
  • Requirement for antihypertensive medication within one week of delivery
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • LV \<50% or history of clinical heart failure with reduced or preserved ejection fraction
  • Hypertrophic or other genetic cardiomyopathy
  • Hyperkalemia: potassium >5.3 mEq/L
  • at screening ≥50 kg/m2
  • Pre-pregnancy diabetes
  • Estimated (eGFR) \<60mL/min/1.73 m2
  • Cirrhosis
  • Primary aldosteronism
  • Intention to become pregnant within 9 months
  • Active substance abuse
  • Other serious medical illnesses or concerns about protocol adherence/ mortality within 9 months
  • Participation in another interventional clinical study
  • to spironolactone
  • Addison's disease
  • Concomitant use of eplerenone or finerenone
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
204 participants (estimated)

Study arms

  • Placebo comparator
    Placebo: Control

    Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.

    Drug: Placebo tablet to match spironolactone

  • Experimental
    Treatment: Spironolactone

    Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.

    Drug: spironolactone 25 mg orally once daily

Interventions

  • DrugSpironolactoneStudies of SpironolactoneSpironolactone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants with hypertensive disorders of pregnancy will receive 25mg capsules of spironolactone to self-administer daily over the 12-week duration of the study treatment.

  • DrugPlacebo tablet to match spironolactone

    Participants with Hypertensive disorders of pregnancy will receive placebo equivalent capsules to self-administer daily over the 12-week duration of the study treatment.

06

What researchers measure

Primary outcomes

  1. Mean 24-hour ambulatory diastolic blood pressure

    24-hour BP monitoring will be performed as part of end-of-study assessments using a validated ambulatory BP monitor.

    Time frame: 36 weeks

Secondary outcomes

  1. Left ventricular relative wall thickness (main echocardiographic outcome)

    Relative wall thickness is calculated as 2\*posterior wall thickness/LV end-diastolic diameter as measured by transthoracic echocardiography.

    Time frame: Baseline and 36 weeks

  2. Mean 24-hour ambulatory systolic blood pressure

    24-hour BP monitoring will be performed as part of end-of-study assessment using a validated ambulatory BP monitor. Mean 24-hour systolic BP will be calculated from the device data.

    Time frame: 36 weeks

  3. Mean diurnal ambulatory systolic blood pressure

    24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean diurnal systolic BP will be calculated from the device data.

    Time frame: 36 weeks

  4. Mean diurnal ambulatory diastolic blood pressure

    24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean diurnal ambulatory diastolic blood pressure will be calculated from the device data

    Time frame: 36 weeks

  5. Mean nocturnal ambulatory systolic blood pressure

    24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean nocturnal ambulatory systolic blood pressure will be calculated from the device data.

    Time frame: 36 weeks

  6. Mean nocturnal ambulatory diastolic blood pressure

    24-hour BP monitoring will be performed as part of the post-treatment assessments using a validated ambulatory BP monitor. Mean nocturnal ambulatory diastolic blood pressure will be calculated from the device data.

    Time frame: 36 weeks

  7. Measured systolic blood pressure

    At each visit, BP will be measured by study staff three times at one-minute intervals in accordance with multi-society guidelines for accurate measurement of blood pressure. The first measurement will be discarded, and the average of the second and third measurements will be recorded as the measured BP at each study visit.

    Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks

  8. Measured diastolic blood pressure

    At each visit, BP will be measured by study staff three times at one-minute intervals in accordance with multi-society guidelines for accurate measurement of blood pressure. The first measurement will be discarded, and the average of the second and third measurements will be recorded as the measured BP at each study visit.

    Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks

  9. Readmission for hypertension

    Postpartum readmission for hypertension will be captured.

    Time frame: Through study completion (36 weeks post-randomization)

  10. All-cause readmission

    All postpartum readmission will be captured

    Time frame: Through study completion (36 weeks post-randomization)

  11. Daily defined doses of antihypertensive medication

    Daily defined doses of antihypertensive medication will be quantified in accordance with the World Health Organization classification.

    Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks

  12. Time to discontinuation of all non-study drug antihypertensive medications

    All medication changes made by treating clinicians will be captured.

    Time frame: Through study completion (36 weeks post-randomization)

  13. Escalation of antihypertensive regimen

    All medication changes made by treating clinicians will be captured.

    Time frame: Through study completion (36 weeks post-randomization)

  14. Ratio of mitral E velocity to e' [E/e']

    E/e', a measure of diastolic function, will be measured by transthoracic echocardiography.

    Time frame: Baseline and 36 weeks

  15. Early diastolic septal mitral annular velocity [septal e']

    Septal e', a measure of diastolic function, will be measured by transthoracic echocardiography using tissue Doppler

    Time frame: Baseline and 36 weeks

  16. Peak tricuspid regurgitant jet velocity

    Peak tricuspid regurgitant jet velocity, a measure of diastolic function, will be measured by transthoracic echocardiography using continuous wave Doppler

    Time frame: Baseline and 36 weeks

  17. Left atrial volume index

    Left atrial volume index will be measured by transthoracic echocardiogarphy using the biplane method and indexed for body surface area.

    Time frame: Baseline and 36 weeks

  18. Ratio of E to A [E/A]

    E/A, a measure of diastolic function, will be measured by transthoracic echocardiography.

    Time frame: Baseline and 36 weeks

  19. Left ventricular mass index

    Left ventricular mass will be calculated from transthoracic echocardiogarphy using the Devereux formula and indexed for body surface area

    Time frame: Baseline and 36 weeks

  20. Left ventricular ejection fraction

    Left ventricular ejection fraction will be measured by transthoracic echocardiogarphy using the biplane method.

    Time frame: Baseline and 36 weeks

  21. Left atrial reservoir strain

    Left atrial strain, a sensitive measure of end- diastolic pressure and atrial remodeling, will be quantified using TOMTEC.

    Time frame: Baseline and 36 weeks

  22. Peak global longitudinal strain

    Left ventricular global longitudinal strain, a measure of subclinical cardiac dysfunction, will be quantified using TOMTEC.

    Time frame: Baseline and 36 weeks

  23. Interventricular septal wall thickness

    Interventricular septal wall thickness will be measured by transthoracic echocardiography from the parasternal long axis view.

    Time frame: Baseline and 36 weeks

  24. Posterior wall thickness

    Posterior wall thickness will be measured by transthoracic echocardiography from the parasternal long axis view.

    Time frame: Baseline and 36 weeks

  25. High-sensitivity cardiac troponin I

    High-sensitivity cardiac troponin will be measured using standard clinical assays.

    Time frame: Baseline, 12 weeks, and 36 weeks

  26. N-terminal pro-B-type natriuretic peptide

    NT-proBNP will be measured using standard clinical assays.

    Time frame: Baseline, 12 weeks, and 36 weeks

  27. Urine microalbumin/creatinine

    Urine microalbumin/creatinine will be measured using standard clinical assays.

    Time frame: 2 weeks, 12 weeks, and 36 weeks

  28. Activin A

    Activin A will be measured by ELISA.

    Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks

  29. Soluble fms-like tyrosine kinase receptor-1

    sFlt-1 will be measured by ELISA.

    Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks

  30. Placental growth factor

    Placental growth factor will be measured by ELISA.

    Time frame: Baseline, 2 weeks, 12 weeks, and 36 weeks

  31. Procollagen type I carboxyterminal propeptide

    PICP will be measured by enzyme immunoassay.

    Time frame: Baseline, 12 weeks, and 36 weeks

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 27, 2025
StartActual
Oct 16, 2025
Primary completionEst.
Dec 2, 2027
CompletionEst.
Mar 2, 2029
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07041281
Collaborators
Brigham and Women's Hospital, University of Pittsburgh Medical Center
Responsible party
Michael C. Honigberg (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Jun 27, 2025
Start date
Oct 16, 2025
Primary completion
Dec 2, 2027 (estimated)
Completion
Mar 2, 2029 (estimated)
Last update
Apr 3, 2026

Study contacts

Michael C Honigberg, MD, MPP
Contact
mhonigberg@mgh.harvard.edu
617-726-1843

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spironolactone

Start the discussion